BU-NOT-SET

CONTACT US
The QbD approach: Key advantages in clinical and commercial phases
  • Analytical chemistry
Lab
Insight
Sustainability report 2020
  • Sustainability
Report
Report
Recipharm and Oncopeptides: Successful collaboration in the development of melflufen, a peptidase-potentiated alkylating agent in clinical trials
  • Drug substance
Man at poster
Poster
Recipharm Analytical Solutions™
  • Analytical chemistry
Icon
Fact sheet
Impurity identification
  • Analytical chemistry
Woman inserting vials in machine
Fact sheet
Stability studies
  • Analytical chemistry
hand holding vials plate
Fact sheet
Extractables & leachables testing
  • Analytical chemistry
Product mix
Fact sheet
Pharmaceutical mergers and acquisitions: opportunities and drivers for CDMOs
  • Industry trends
Eyes
Insight
Global expansion in the CDMO field
  • Industry trends
Eyes
Insight
Insight
  • Drug product
  • Industry trends
Challenges and solutions to enhancing mRNA stability with lyophilisation processes
Insight
  • Industry trends
  • Manufacturing
A well-equipped CDMO for OSD contract manufacturing
Insight
  • Analytical chemistry
  • Industry trends
Optimising efficiency with technological innovation in analytical testing
Brochure
  • Biologics
Progress your biologic with Advanced Bio comprehensive services
Insight
  • Biologics
Innovation & leadership across the advanced therapy space
Insight
  • Biologics
Overcoming oncolytic virus obstacles with the help of a CDMO partnership
Webinar
  • Biologics
Webinar: Beyond borders: Navigating global scale-up for viral-based therapies
eBook
  • Drug product
Choosing the right container for your sterile drug product
White paper
  • Biologics
Cell and virus banking in OV development and manufacturing